UCB To Buy Ra for $2.1bn And Plays Down Antitrust Fears
Getting hold of zilucoplan, a 'pipeline in a product'
The deal, welcomed by analysts, means that the Belgian drug maker has two late-stage products for the rare disease myasthenia gravis to challenge Alexion's Soliris.
You may also be interested in...
Private Company Edition: Recent biopharma venture capital financings add up to $1.7bn, including a $135m crossover round for HilleVax after spinning out of Takeda in July to advance a norovirus vaccine, Skyhawk’s $133m in fresh funding and Obsidian’s $115m series B round.
The Brussels-based company has leant on its local knowledge to snap up Leuven-headquartered biotech Handl and its proprietary AAV capsid technology platform.
Argenx's efgartigimod, an antibody fragment that blocks FcRn, looks most likely to be the first drug to challenge Alexion's Soliris in the myasthenia gravis market after the company presented more positive data from the ADAPT trial.